Akums launches generic formulation to treat migraine
时间:2024-09-29 02:51:50 阅读(143)
Akums Drugs & Pharmaceuticals Ltd., a contract manufacturing pharmaceutical company, on Friday announced that it has launched the Lasmiditan tablet which is prescribed to treat migraine. This medication has received approvals from the Drug Controller General of India (DCGI) and the United States Food and Drug Administration (USFDA).
It is the generic formulation of Eli Lilly’s REYVOW which is indicated for treatment of acute migraine.
In a 2019 report, it was revealed that headache disorders, including both migraines and tension-type headaches, have emerged as the most prevalent neurological conditions in India, affecting an astonishing 488 million individuals.
The International Headache Society (IHS) outlines criteria for diagnosing migraine, including specific characteristics and associated symptoms observed in at least five attacks. Two main subtypes, migraine without aura and migraine with aura, present distinct features, with the latter involving focal neurological symptoms preceding or accompanying the headache.
“Migraine poses a significant global impact. According to a 2019 report, headache disorders, encompassing migraine and tension-type headaches, emerged as the most widespread neurological conditions in India, impacting a staggering 488 million individuals. Despite this substantial prevalence and the resulting disability, migraine awareness among patients remains inadequate. Compounded by frequent misdiagnosis as other headache disorders, these factors contribute to an increased burden associated with migraine. In light of this, Akums aims to provide a solution for managing this condition with the introduction of the Lasmiditan tablet,” Sanjeev Jain, Joint Managing Director, Akums Drugs & Pharmaceuticals Ltd., said.
猜你喜欢
- Share Market Highlights- Nifty adds 100 pts from day’s low, ends above 18300, Sensex higher by 0
- Rupee likely to depreciate on strong dollar, risk aversion in equity markets; USDINR to trade in this range
- Rupee gains 21 paise to close at 82
- Google releases “Ready for Builders” blog to address Privacy Sandbox objections
- Rupee drops, but confidence on RBI largely caps losses
- Share Market Highlights- Nifty ends above 19400, Sensex soars 270 pts; Bank Nifty below 44750, UPL, Bajaj Finance fall
- Gold Price Today, 6 September 2022- Gold prices top Rs 50600 on fall in US Dollar; check support, resistance
- Share Market Highlights- Nifty under 19300, Sensex sinks 0
- Gold Rates- MCX gold inches higher on weaker US Dollar, Treasury Yields; support is seen at Rs 62120-61850, resistance at Rs 62780-63000